Strativa gains FDA approval of nausea drug Zuplenz

07/5/2010 | Wall Street Journal, The

Strativa Pharmaceuticals, a subsidiary of Par Pharmaceutical, obtained FDA approval to launch Zuplenz for the prevention of nausea and vomiting induced by radiotherapy, surgery and chemotherapy. The treatment will be sold as an oral soluble film, developed using technology from MonoSol Rx.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Various Health Care and IT Positions
Centers for Medicare & Medicaid Services
Baltimore, Bethesda, MD
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Executive Vice President-MyHealth First Network
Greenville Health System
Greenville, SC